CNS/Neurology, Clinical Pharmacology - Cardiology
Since 2007, Dr. Marcus Jerling serves as TFS Medical Scientific Advisor in clinical drug development and has been extensively involved in the design, execution and evaluation of early phase clinical trials in several therapeutic areas including CNS, cardiovascular, diabetes and bleeding disorders.
Dr. Jerling is a licensed Medical Doctor with board certification in Clinical Pharmacology. He holds a PhD from the Karolinska Institute in pharmacokinetic-pharmacodynamic modeling. Dr. Jerling initially practiced medicine for several years in the areas of anesthesiology, pulmonary medicine and psychiatry and joined the pharmaceutical industry in 1995 heading several Clinical Pharmacology Units and R&D Departments at Astra Arcus, Pharmacia, CV Therapeutics and Novo Nordisk.
His research interests include the dose dependency of drug effects, drug development strategies including the use of biomarkers, and safety evaluation of drug candidates. He is a member of the American College of Clinical Pharmacology and the American Society for Clinical Pharmacology and Therapeutics, and a referee for several scientific journals in the area of Clinical Pharmacology.